Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$5.00 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$15.09M
Enterprise Value$58.27
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding1,779,275
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$47.50Price Target Upside195.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.23
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Non-dilutive Partnership FundingMaterial upfronts and milestone receipts from partners provide non‑dilutive capital, validate external interest in the pipeline, and directly fund operations and development. This durable funding reduces near‑term equity issuance risk and supports IND timelines and program advancement.
Low Financial LeverageVery low debt levels limit fixed financing burdens and reduce bankruptcy risk, giving management flexibility to prioritize R&D or partner deals. Over months this improves financial optionality versus highly levered peers, especially for a development‑stage biotech.
Peptide MC4R Program Advancing To INDA defined IND timetable for the once‑weekly peptide creates a clear, multi‑quarter development milestone sequence that can unlock partnering, regulatory interaction, or value inflection. Progress toward submission is a lasting fundamental de‑risking step for the franchise.
Bears Say
Significant Cash Burn & Limited RunwaySustained negative operating cash flow and a runway to mid‑2027 force dependency on milestone receipts or financing. This structurally elevates dilution and execution risk, constrains long‑term planning, and could delay programs if expected receipts or timing slip.
Persistent Unprofitability On Small Revenue BaseHigh gross margins contrast with recurring large operating losses and inconsistent top‑line. A small, volatile revenue base leaves R&D and commercialization reliant on partner payments rather than internal cash generation, weakening long‑term self‑funding ability.
Competitive & Timing Risks To CommercializationAn approved competitor and delayed oral program create structural commercial headwinds. Being years behind in some indications and reprioritizing earlier oral candidates reduces first‑mover opportunities and may compress addressable markets when Palatin reaches clinic.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $5.00 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $15.09M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 117 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN Stock 12 Month Forecast
Average Price Target
$47.50
▲(195.95% Upside)
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
11.21% Insiders
1.96% Mutual Funds
<0.01% Other Institutional Investors
85.46% Public Companies and
Individual Investors